Oxycodone Patent Expiration
Oxycodone is Used for managing severe, chronic pain when other treatment options are insufficient. It was first introduced by Collegium Pharmaceutical Inc
Oxycodone Patents
Given below is the list of patents protecting Oxycodone, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xtampza Er | US10188644 | Process of making stable abuse-deterrent oral formulations | Sep 02, 2036 | Collegium Pharm Inc |
| Xtampza Er | US10646485 | Process of making stable abuse-deterrent oral formulations | Sep 02, 2036 | Collegium Pharm Inc |
| Xtampza Er | US9737530 | Process of making stable abuse-deterrent oral formulations | Sep 02, 2036 | Collegium Pharm Inc |
| Xtampza Er | US9968598 | Process of making stable abuse-deterrent oral formulations | Sep 02, 2036 | Collegium Pharm Inc |
| Xtampza Er | US10004729 | Tamper-resistant pharmaceutical compositions of opioids and other drugs | Dec 10, 2030 | Collegium Pharm Inc |
| Xtampza Er | US10668060 | Tamper-resistant pharmaceutical compositions of opioids and other drugs | Dec 10, 2030 | Collegium Pharm Inc |
| Xtampza Er | US9682075 | Tamper-resistant pharmaceutical compositions of opioids and other drugs | Dec 10, 2030 | Collegium Pharm Inc |
| Xtampza Er | US7771707 | Abuse-deterrent drug formulations | Oct 09, 2028 | Collegium Pharm Inc |
| Xtampza Er | US8758813 | Abuse-deterrent drug formulations |
Jun 10, 2025
(Expired) | Collegium Pharm Inc |
| Xtampza Er | US7399488 | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
Mar 24, 2025
(Expired) | Collegium Pharm Inc |
| Xtampza Er | US8449909 | Abuse-deterrent drug formulations |
Mar 24, 2025
(Expired) | Collegium Pharm Inc |
| Xtampza Er | US8557291 | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
Mar 21, 2025
(Expired) | Collegium Pharm Inc |
| Xtampza Er | US10525052 | Abuse-deterrent drug formulations |
Jul 07, 2023
(Expired) | Collegium Pharm Inc |
| Xtampza Er | US10525053 | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
Jul 07, 2023
(Expired) | Collegium Pharm Inc |
| Xtampza Er | US8840928 | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
Jul 07, 2023
(Expired) | Collegium Pharm Inc |
| Xtampza Er | US9044398 | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
Jul 07, 2023
(Expired) | Collegium Pharm Inc |
| Xtampza Er | US9248195 | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
Jul 07, 2023
(Expired) | Collegium Pharm Inc |
| Xtampza Er | US9592200 | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
Jul 07, 2023
(Expired) | Collegium Pharm Inc |
| Xtampza Er | US9763883 | Abuse-deterrent drug formulations |
Jul 07, 2023
(Expired) | Collegium Pharm Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Oxycodone's patents.
Latest Legal Activities on Oxycodone's Patents
Given below is the list recent legal activities going on the following patents of Oxycodone.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Maintenance Fee Reminder Mailed | 09 Feb, 2026 | US8758813 |
| Patent Term Extension Certificate | 02 Jan, 2026 | US7771707 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 10 Dec, 2025 | US10004729 |
| Withdrawal of Application for PTE | 26 Nov, 2025 | US7399488 |
| Withdrawal of Application for PTE | 26 Nov, 2025 | US8449909 |
| Election in Response to Notice of Final Determination | 21 Nov, 2025 | US8449909 |
| Election in Response to Notice of Final Determination | 21 Nov, 2025 | US7399488 |
| FDA Final Eligibility Letter | 21 Nov, 2025 | US7399488 |
| FDA Final Eligibility Letter | 21 Nov, 2025 | US7771707 |
| Election in Response to Notice of Final Determination | 21 Nov, 2025 | US7771707 |
Oxycodone's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Oxycodone:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
